ribosomal protein S15Genealiases: RIG · S15 · uS19
Q-omics provides the consensus-scored RPS15 profile across patient tissues and cancer cell-line models. RPS15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS15 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RPS15 protein abundance shows 28,226 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where RPS15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15 survival associations across molecular data types. RPS15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15 RNA expression–survival associations across cancer types. High RPS15 expression shows unfavorable associations in ACC, KIRP, LIHC, KICH and COAD, but favorable associations in UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS15 RNA expression.
This table summarizes RPS15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPS15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15 shows higher tumor expression in KIRC, COAD, LIHC, KIRP, CHOL and READ. The KIRC box plot shows higher RPS15 RNA expression in tumor versus normal tissue (log2 FC = +0.995, t-test p < 0.001).
This table shows molecular features associated with RPS15 in patient tissues and cancer cell lines. In patient samples, RPS15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
